3

NCT05070546 – A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Safety and Immunogenicity of an Ad26.RSV.preF-based Vaccine in Adults Aged 18 to 59 Years, Including Those at High-risk for Severe RSV

Posted on March 18, 2025 by Molly Willeford -

NCT05071313 – A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older

Posted on March 18, 2025 by Molly Willeford -

NCT05083585 – A Randomized, Double-blind Phase 3 Study to Compare the Immunogenicity of Clinical Trial Material of an Ad26.RSV.preF-based Vaccine for Phase 3 With Clinical Trial Material Representative of Phase 2b in Adults Aged 60 to 75 Years

Posted on March 18, 2025 by Molly Willeford -

NCT05101486 – A Randomized, Double-blind Phase 3 Study to Assess the Immunogenicity and Safety of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years

Posted on March 18, 2025 by Molly Willeford -

Clinical Evaluation of Risperidone versus Haloperidol in Treatment Resistant Chronic Schizophrenic Patients

Posted on March 5, 2025 by Molly Willeford -

NCT03775421 – Prospective, Multi-center, Single-arm, Open-label Long-term Study Assessing the Safety, Tolerability, and Effectiveness of Macitentan in Fontan-palliated Adult and Adolescent Subject (RUBATO OL)

Posted on January 21, 2025 by Molly Willeford -

NCT03153137 – Prospective, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Adult and Adolescent Subjects (RUBATO DB)

Posted on January 21, 2025 by Molly Willeford -

NCT02703272 – A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma

Posted on October 28, 2024 by Molly Willeford -

NCT00367237 – A Randomized, Multicenter, International, Open-label Study of Infliximab Plus Methotrexate Versus Methotrexate (MTX) Alone for the Treatment of MTX naïve Subjects With Active Psoriatic Arthritis

Posted on May 15, 2024 by Jessica Ritchie -

NCT00051623 – A Multicenter, Randomized, Double-blind Trial of Anti-TNFa Chimeric Monoclonal Antibody (Infliximab) for the Treatment of Patients With Psoriatic Arthritis

Posted on May 9, 2024 by Jessica Ritchie -